2015
DOI: 10.1016/j.jjcc.2014.07.010
|View full text |Cite
|
Sign up to set email alerts
|

Gender differences in the clinical features of hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations

Abstract: Although females with MYBPC3 mutations showed later onset of the disease, female patients were more symptomatic at diagnosis and had more frequent heart failure events once they had developed hypertrophy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
30
1
2

Year Published

2015
2015
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 39 publications
(35 citation statements)
references
References 25 publications
1
30
1
2
Order By: Relevance
“…Hypertrophic cardiomyopathy (HCM) is a complex primary and genetic cardiac disease with heterogeneous clinical expression, characterized by a benign or stable clinical course over many years, progressive congestive heart failure symptoms requiring therapeutic intervention, and the possibility of systemic embolic events and sudden unexpected death [1][2][3][4][5][6].…”
Section: Introductionmentioning
confidence: 99%
“…Hypertrophic cardiomyopathy (HCM) is a complex primary and genetic cardiac disease with heterogeneous clinical expression, characterized by a benign or stable clinical course over many years, progressive congestive heart failure symptoms requiring therapeutic intervention, and the possibility of systemic embolic events and sudden unexpected death [1][2][3][4][5][6].…”
Section: Introductionmentioning
confidence: 99%
“…Familial HCM, which has a prevalence of up to 1 in 500 individuals, is one of the most common autosomal dominant inherited disorders [6]. Myosin heavy chain (MYH7, OMIM#: 160760), myosin binding protein C (MYBPC3, OMIM#: 600958), troponin T (TNNT2, OMIM#: 191045), tropomyosin (TPM1, OMIM#: 191010), and troponin I (TNNI3, OMIM#: 191044) have been reported to be the main causal genes [2][3][4][7][8][9][10][11]. To date, candidate-gene approaches using traditional Sanger sequencing have enabled the identification of causative variants in approximately 50% of HCM patients [8].…”
Section: Introductionmentioning
confidence: 99%
“…Известно, что идиопатическая ГКМП характери-зуется различным возрастом манифестации первых клинических проявлений заболевания, многообра-зием клинических и морфологических признаков [2,[6][7][8]. Эта фенотипическая гетерогенность обуслов-лена как генетическими причинами, такими как патогенные генетические дефекты [6][7][8] и поли-морфные варианты генов-модификаторов, так и негенетическими потенциально модифицируе-мыми факторами кардиометаболического риска (ожирение, артериальная гипертензия) [8].…”
unclassified
“…Эта фенотипическая гетерогенность обуслов-лена как генетическими причинами, такими как патогенные генетические дефекты [6][7][8] и поли-морфные варианты генов-модификаторов, так и негенетическими потенциально модифицируе-мыми факторами кардиометаболического риска (ожирение, артериальная гипертензия) [8]. Известно, что демографические детерминанты -пол и воз-раст -вносят свой вклад в особенности течения многих заболеваний сердечно-сосудистой системы, в том числе, идиопатической ГКМП [9].…”
unclassified